5 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 1 with a minor change only.
Primary and study completion pushed from Jun 1, 2027 to Jun 1, 2029
Roswell Park Cancer InstitutePhase 1/2 NCT06307548 Registry history of NCT06307548 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Oct 21, 2026 to Jul 29, 2027
Also in this update: Study completion moved earlier from Sep 1, 2029 to Jul 29, 2027
Roswell Park Cancer InstitutePhase 2 NCT04876248 Registry history of NCT04876248 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jan 15, 2028 to Aug 18, 2028
Also in this update: Study completion pushed from Jan 15, 2030 to Aug 18, 2030
Roswell Park Cancer InstitutePhase 1 NCT07489287 Registry history of NCT07489287 on ClinicalTrials.gov (opens the registry)
Updated
Results posted: Sep 21, 2026
Also in this update: Study completion pushed from Jun 14, 2026 to Sep 14, 2026
Roswell Park Cancer InstitutePhase 2 NCT04032418 Registry history of NCT04032418 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 25, 2026 to Dec 25, 2026
Roswell Park Cancer InstituteNot applicable NCT03897270 Registry history of NCT03897270 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-05 | NCT07857681 Text Message and Mail Delivery of Tailored Educational Materials to Improve Access to… | Active, Not Recruiting |
| Early Phase 1 | 3 | |
| Phase 1 | 12 | |
| Phase 1/2 | 8 | |
| Phase 2 | 22 | |
| Phase 3 | 1 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men… | Localized Prostate Carcinoma | Recruiting | 2026-05-14 |
| Phase 3 | ||||
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic… | Oligometastasis | Recruiting | 2026-02-04 |
| Phase 2 | ||||
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse… | Richter Syndrome | Recruiting | 2026-10-02 |
| NCT06821997 | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal… | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | 2026-09-21 |
| NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and… | Non-Muscle Invasive Bladder Carcinoma | Recruiting | 2026-09-17 |
| NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative… | Early Stage Lung Non-Small Cell Carcinoma | Recruiting | 2026-08-26 |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11… | Advanced Lung Non-Small Cell Carcinoma | Recruiting | 2026-08-19 |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory… | Extramedullary Disease in Multiple Myeloma | Recruiting | 2026-08-18 |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing… | Cancer-Associated Anorexia | Recruiting | 2026-08-18 |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… | Ovarian Clear Cell Adenocarcinoma | Recruiting | 2026-08-14 |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain… | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting | 2026-07-21 |
| NCT04067830 | Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients… | Stage I Lung Cancer AJCC v8 | Recruiting | 2026-05-18 |
| NCT04068649 | Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients… | Metastatic Malignant Neoplasm | Recruiting | 2026-04-30 |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting | 2026-04-24 |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab… | Fallopian Tube Carcinosarcoma | Recruiting | 2026-03-23 |
| NCT04682158 | Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | Recruiting | 2026-01-02 |
| NCT05651594 | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment… | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Recruiting | 2025-12-16 |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage… | Extensive Stage Lung Small Cell Carcinoma | Recruiting | 2025-12-15 |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients… | Plasma Cell Myeloma | Active, Not Recruiting | 2026-09-25 |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small… | Lung Non-Small Cell Carcinoma | Active, Not Recruiting | 2026-09-21 |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non… | Advanced Lung Non-Small Cell Carcinoma | Not Yet Recruiting | 2026-09-02 |
| NCT06827054 | Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring… | Hematopoietic and Lymphatic System Neoplasm | Not Yet Recruiting | 2026-08-12 |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed… | Glioblastoma | Active, Not Recruiting | 2026-08-07 |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With… | Prostate Adenocarcinoma | Active, Not Recruiting | 2026-06-09 |
| Phase 1/2 | ||||
| NCT06307548 | Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for… | Locally Advanced Colorectal Carcinoma | Recruiting | 2026-10-15 |
Lung Cancer (14) · Breast Cancer (8) · Non-Small Cell Lung Cancer (NSCLC) (8) · Colorectal Cancer (6) · Leukemia (6) · Multiple Myeloma (6) · Ovarian Cancer (6) · Prostate Cancer (6) · Head & Neck Cancer (5) · Sarcoma (4)